Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer

Liangliang Bai1 Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan610041, People’s Republic of China;2 West China Biomedical Big Data Center, Sichuan University, Chengdu, Sichuan610041, People’s Republic of China

Pengfei Zhang1 Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan610041, People’s Republic of China;2 West China Biomedical Big Data Center, Sichuan University, Chengdu, Sichuan610041, People’s Republic of China

Kexun Zhou1 Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan610041, People’s Republic of China;2 West China Biomedical Big Data Center, Sichuan University, Chengdu, Sichuan610041, People’s Republic of China

Weiting Liao1 Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan610041, People’s Republic of China;2 West China Biomedical Big Data Center, Sichuan University, Chengdu, Sichuan610041, People’s Republic of China

Qiu Li1 Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan610041, People’s Republic of China;2 West China Biomedical Big Data Center, Sichuan University, Chengdu, Sichuan610041, People’s Republic of ChinaCorrespondence[email protected]

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Articles from other publishers (7)

Zixuan He, Xianqin Huang, Dingyi Chen, Guoan Wang, Yuezhen Zhu, Huangqianyu Li, Sheng Han, Luwen Shi & Xiaodong Guan. (2023) Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review. BMJ Global Health 8:11, pages e012780.
Crossref

Septiara Putri, Siti Rizny F. Saldi, Levina Chandra Khoe, Ery Setiawan, Amila Megraini, Benjarin Santatiwongchai, Ryan R. Nugraha, Vetty Y. Permanasari, Mardiati Nadjib, Sudigdo Sastroasmoro & Armansyah Armansyah. (2023) Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting. BMC Cancer 23:1.
Crossref

Yin Liu, Xi Zhang, Hui-Fang Xu, Ji-Hai Shi, Yu-Qian Zhao, Ling-Bin Du, Yun-Yong Liu, Wen-Jun Wang, He-Lu Cao, Li Ma, Juan-Xiu Huang, Ji Cao, Li Li, Yan-Ping Fan, Xiao-Fen Gu, Chang-Yan Feng, Qian Zhu, Xiao-Hui Wang, Jing-Chang Du, Jian-Gong Zhang, Shao-Kai Zhang & You-Lin Qiao. (2023) Real-World Utilization, Barriers, and Factors Associated With the Targeted Treatment of Metastatic Colorectal Cancer Patients in China: A Multi-Center, Hospital-Based Survey Study. International Journal of Public Health 68.
Crossref

Abdosaleh Jafari, Sedighe Sadat Tabatabaei Far, Mehdi Dehghani & Ramin Ravangard. (2023) Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran. Cancer Control 30.
Crossref

Takashi Morimoto, Kaori Fujito, Bumpei Yamasaki & Rei Goto. (2023) Cost-effectiveness Analysis of Monoclonal Antibodies in the First-line Treatment of RAS Wild-type Metastatic Colorectal Cancer: A Systematic Review. Clinical Therapeutics 45:1, pages 41-54.
Crossref

Liu Liu, Zhixin Jiang, Fuming Li, Yan Wei, Jian Ming, Yi Yang, Shimeng Liu, Lizheng Shi & Yingyao Chen. (2022) Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list. BMC Health Services Research 22:1.
Crossref

Difei Yao, Lingyan Yu, Wei He, Yangmin Hu, Huimin Xu, Ying Yuan & Haibin Dai. (2021) Antineoplastic prescription among patients with colorectal cancer in eight major cities of China, 2015–2019: an observational retrospective database analysis. BMJ Open 11:10, pages e046166.
Crossref

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer

Articles from other publishers (7)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer

Citations (7)

Articles from other publishers (7)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date